TUMOUR REVIEWRadiotherapeutic management of brain metastases: A systematic review and meta-analysis
Introduction
The management of brain metastases is a significant health care problem. An estimated 20–40% of cancer patients will develop metastatic cancer to the brain during their illness. While most of these patients will develop symptomatic brain metastases, some may be asymptomatic.1 The burden of brain metastases impacts on the quality and length of survival. Presenting symptoms include headache (49%), focal weakness (30%), mental disturbances (32%), gait ataxia (21%), seizures (18%), speech difficulty (12%), visual disturbance (6%), sensory disturbance (6%), and limb ataxia (6%).2
Brain metastases may develop from any primary tumour site, the most common primary sites being the lung, followed by the breast and the gastrointestinal region.3 Eighty-five percent of brain metastases are found in the cerebral hemispheres, 10–15% in the cerebellum, and 1–3% in the brainstem.4 The literature suggests that patients with breast or lung cancer metastatic to brain are likely to show size reduction of brain metastases with whole brain radiotherapy (WBRT). Patients with melanoma or renal cancer metastatic to brain are less likely to show a reduction in the size of brain metastases with WBRT.5
Important prognostic factors for patients with brain metastases include age, performance status, and the status of extracranial disease. The Radiation Therapy Oncology Group (RTOG) analyzed 1200 patients from three consecutive RTOG trials that tested several dose-fractionation schemes of WBRT and radiosensitizers in the management of patient with brain metastases. Using recursive partitioning analysis (RPA), three prognostic groups were produced. The best survival with a median of 7.1 months was categorized as RPA class I and was seen in patients <65 years of age, with Karnofsky performance status (KPS) of at least 70 and a controlled primary tumour with the brain as the only site of metastases. The worst survival (median 2.3 months) categorized as RPA class III, consisted of patients with KPS less than 70. All other patients fit into RPA class II with a median survival of 4.2 months.38
This systematic review was completed by the Supportive Care Guidelines Group of Cancer Care Ontario’s Program in Evidence-based Care in the context of developing an evidence-based practice guideline. Using the methods of the Practice Guidelines Development Cycle,6 this review will be combined with practitioner feedback to formulate a clinical practice guideline on the optimal radiotherapeutic management of brain metastases. The practice guideline component, outlining the external review process and recommendations, is currently under consideration for publication.7
Section snippets
Literature search strategy
MEDLINE (1966 to June 2004), CANCERLIT (1975 to 2003), CINAHL (1982 to June 2004), EMBASE (1980 to 2004 week 25), and the Cochrane Library (2004, Issue 2) databases were searched through Ovid. The terms “brain neoplasms” (Medical subject heading [MeSH]), “metastas#s” (text word), and “metastatic brain” were combined with the MeSH terms ”radiotherapy”, “radiotherapy, adjuvant”, “combined modality therapy”, “chemotherapy”, “surgery”, and “radiosurgery”. These were combined with terms for the
Single brain metastasis
Three trials evaluated the role of surgery plus WBRT compared with WBRT alone.10, 11, 12 One trial assessed the effectiveness of surgery plus WBRT versus surgery alone.13 One trial examined the use of radiosurgery boost with WBRT versus WBRT alone in selected patients with one to three brain metastases.14
Multiple brain metastases
One randomized controlled trial examined the use of supportive care alone (through oral prednisone) versus supportive care and WBRT.15 Nine studies examined the use of altered WBRT
Single brain metastasis
The pooled results of three trials10, 11, 12 using WBRT with or without surgical excision showed no difference in overall mortality at 6 months (RR 0.72; 95% CI 0.39, 1.32; p = 0.28). In contrast, two11, 12 of the three trials reported a statistically significant improvement in overall median survival. In the Noordijk et al. trial [11], overall median survival was 6 months in the WBRT alone arm and 10 months in the WBRT and surgery arm, p = 0.04. In the Patchell et al. study [12], overall median
Conclusions
Patients with brain metastases represent a heterogeneous group. A proportion may benefit from aggressive treatment for brain metastases (surgery, radiosurgery, WBRT) and systemic therapy for extracranial disease. It is important to note, however, that patients with brain metastases who enter into trials tend to be of better pronosis than the larger number of patients who do not enter trials. These latter patients with poor prognoses (such as those with poor KPS and active progressive
References (38)
- et al.
Assessing the quality of reports of randomized clinical trials. Is blinding necessary?
Controlled Clin Trials
(1996) - et al.
The choice of treatment of single brain metastasis should be based on extracranial tumour activity and age
Int J Radiat Oncol Biol Phys
(1994) - et al.
Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases; phase III results of the RTOG 9508 randomised trial
The Lancet
(2004) - et al.
Results of a randomized clinical trial comparing two radiation schedules in the palliative treatment of brain metastases
Radiother Oncol
(1993) - et al.
Ultra-rapid high dose irradiation schedules for the palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group
Int J Radiat Oncol Biol Phys
(1981) - et al.
Radiation therapy of cerebral metastases: a randomized prospective clinical trial
Int J Radiat Oncol Biol Phys
(1977) - et al.
The palliation of brain metastases in a favourable patient population: a randomized clinical trial by the Radiation Therapy Oncology Group
Int J Radiat Oncol Biol Phys
(1981) - et al.
A randomized phase III study of accelerated hyperfractionation versus standard in patients with unresected brain metastases: a report of the Radiation Therapy Oncology Group (RTOG) 9104
Int J Radiat Oncol Biol Phys
(1997) - et al.
Final results of the Royal College of Radiologists trial comparing two different radiotherapy schedules in the treatment of cerebral metastases
J Clin Oncol
(1996) - et al.
Results of a randomized comparison of radiotherapy and bromodeoxyuridine with radiotherapy alone for brain metastases: report of RTOG trial 89-05
Int J Radiat Oncol Biol Phys
(1995)
Randomized treatment of brain metastases with gamma knife radiosurgery, whole brain radiotherapy or both [abstract]
Int J Radiat Oncol Biol Phys
Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients multiple brain metastases
Int J Radiat Oncol Biol Phys
Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination inoperable brain metastasis of non-small cell lung cancer: Groupe Française de Pneumo-Cancerologie (GFPC) protocol 95-1
Ann Oncol
Randomized phase III trial of fotemustine versus fotemustine plus whole brain irradiation in cerebral metastases of melanoma
Cancer Radiother
Treatment of metastatic cancer
Epidemiology of brain tumours: the national survey of intracranial neoplasms
Neurology
The treatment of brain metastases
Neurosurgery
Radiation therapy for brain metastases
Ann Neurol
Cited by (125)
Intensity Modulated Radiation Therapy With Simultaneous Integrated Boost in Patients With Brain Oligometastases: A Phase 1 Study (ISIDE-BM-1)
2017, International Journal of Radiation Oncology Biology PhysicsEstimating the need for palliative radiation therapy: A benchmarking approach
2016, International Journal of Radiation Oncology Biology PhysicsDirect Evaluation of Treatment Response in Brain Metastatic Disease with Deep Neuroevolution
2023, Journal of Digital Imaging